검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Nirogacestat |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ADC |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | and role in modulating chemotherapy resistance remain unclear |
MoA Biomarker | BCMA is released into circulation, follow |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | PD |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance.. Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer. Paclitaxel (Taxol) serves as a first-line chemotherapeutic agent, but the emergence of drug resistance often limits its clinical efficacy. Bioactive compound… |
Clinical Primary efficacy | ORR 57% |
Clinical ORR | 57% |
Clinical Result source | ClinicalTrials.gov NCT07150104 |
Clinical Data Tier / Score | A · 52 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Nirogacestat |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ADC |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | and role in modulating chemotherapy resistance remain unclear |
MoA Biomarker | BCMA is released into circulation, follow |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | PD |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance.. Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer. Paclitaxel (Taxol) serves as a first-line chemotherapeutic agent, but the emergence of drug resistance often limits its clinical efficacy. Bioactive compound… |
Clinical Primary efficacy | ORR 57% |
Clinical ORR | 57% |
Clinical Result source | ClinicalTrials.gov NCT07150104 |
Clinical Data Tier / Score | A · 52 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교